The Application of Glucose CEST MR Imaging in Brain Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04945499|
Recruitment Status : Recruiting
First Posted : June 30, 2021
Last Update Posted : July 28, 2021
|Condition or disease||Intervention/treatment||Phase|
|Magnetic Resonance Imaging||Drug: d-glucose||Early Phase 1|
methods： Brain tumor patients were recruited. Time-resolved glucose signal changes were detected using chemical exchange saturation transfer (glucoCEST) MRI. Dynamic glucose enhanced (DGE) MRI was used to measure tissue response to an intravenous bolus of D-glucose. During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times of 250 seconds. Performing contrast enhancement based on Gd-DTPA in 30 minutes later, which was used for comparison as golden standard.
The area of hyperintensity will be measured, which represents the area of brain tumor.
Differential test and Consistency analysis were used for statistical analysis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Evaluation of D-glucose Weighted Chemical Exchange Saturation Transfer (gluceoCEST)-Based Dynamic Glucose Enhanced(DGE) Magnetic Resonance Imaging（MRI） in Brain Tumor|
|Actual Study Start Date :||June 1, 2019|
|Estimated Primary Completion Date :||June 30, 2022|
|Estimated Study Completion Date :||June 30, 2023|
During the dynamic glucose scan, a brief hyperglycemic state was established by intravenous infusion of hospital-grade D50 glucose (D50, 25 g of dextrose in 50 mL of water sterile solution), followed by 20 mL of saline solution in 1 arm. The glucose infusion was performed using a power injector at an infusion rate of 0.2 mL/s, corresponding to total infusion times 250 seconds.
using d-glucose as an contrast agent on CEST MR Imaging
Other Name: 50% dextrose injection
- CEST value of tumor lesion including tumor core/ necrosis/ cysis/ edema [ Time Frame: 1 week ]the CEST value of tumor core and necrosis might higher than white matter
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04945499
|Contact: Zhibo Wen, PhDemail@example.com|
|Contact: Jianhua Mo, MDfirstname.lastname@example.org|
|Zhujiang Hospital of Southern Medical University||Recruiting|
|Guangzhou, Guangdong, China, 510282|
|Contact: zhibo wen, PhD 020-61643461 email@example.com|